Merck, Inc.
🇵🇭Philippines
A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00254553
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 868
- Registration Number
- NCT00251641
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00251589
V930 First in Man (FIM) Study (V930-002)(COMPLETED)
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00250419
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 204
- Registration Number
- NCT00250432
A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 420
- Registration Number
- NCT00246337
Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00245544
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
Phase 3
Withdrawn
- Conditions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00243568
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT00243230
A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00242476
© Copyright 2024. All Rights Reserved by MedPath